公开(公告)号：USRE48863E1

公开(公告)日：2021-12-28

申请号：US16388011

申请日：2019-04-18

申请人： WYETH LLC

发明人： Annaliesa Sybil Anderson ,  Maninder K. Sidhu ,  Robert G. K. Donald ,  Kathrin Ute Jansen ,  Narender K. Kalyan ,  Justin Keith Moran ,  Mark E. Ruppen ,  Michael James Flint

IPC分类号： A61K39/08 ,  C07K14/00 ,  C07K14/33 ,  C07K16/12 ,  C12N9/10 ,  C12N9/99 ,  C12N15/74

摘要： In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may further include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to antibodies or binding fragments thereof that binds to said immunogenic compositions. In further aspects, the invention relates to isolated nucleotide sequences that encode any of the foregoing, and methods of use of any of the foregoing compositions.

公开(公告)号：USRE48862E1

公开(公告)日：2021-12-28

申请号：US16387999

申请日：2019-04-18

申请人： WYETH LLC

发明人： Maninder K. Sidhu ,  Annaliesa Sybil Anderson ,  Robert G. K. Donald ,  Kathrin Ute Jansen ,  Narender K. Kalyan ,  Justin Keith Moran ,  Mark E. Ruppen ,  Michael James Flint

IPC分类号： A61K39/08 ,  C07K14/00 ,  C07K14/33 ,  C07K16/12 ,  C12N9/10 ,  C12N9/99 ,  C12N15/74

摘要： In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may further include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to antibodies or binding fragments thereof that binds to said immunogenic compositions. In further aspects, the invention relates to isolated nucleotide sequences that encode any of the foregoing, and methods of use of any of the foregoing compositions.

公开(公告)号：US20200093914A1

公开(公告)日：2020-03-26

申请号：US16598661

申请日：2019-10-10

申请人： Wyeth LLC

发明人： Annaliesa Sybil Anderson ,  Kathrin Ute Jansen ,  Mark Edward Ruppen ,  Justin Keith Moran ,  Susan Kay Hoiseth

IPC分类号： A61K39/095 ,  C07K14/22

摘要： The present invention relates to compositions including an isolated non-pyruvylated non-lipidated ORF2086 polypeptide, and methods thereof. In an exemplary embodiment, the compositions described herein are immunogenic. The present invention further relates to compositions that elicit a bactericidal immune response in a mammal against an ORF2086 subfamily B polypeptide, from serogroup B Neisseria meningitides, and methods related thereto.

公开(公告)号：US20170313749A1

公开(公告)日：2017-11-02

申请号：US15648092

申请日：2017-07-12

申请人： Wyeth LLC

发明人： Kathrin Ute Jansen ,  Annaliesa Sybil Anderson ,  Robert G.K. Donald ,  Maninder K. Sidhu ,  Narender K. Kaylan ,  Justin Keith Moran ,  Mark E. Ruppen ,  Michael James Flint

IPC分类号： C07K14/33 ,  C12N15/74 ,  C12N9/10 ,  A61K39/08 ,  C07K16/12 ,  C12N9/99

摘要： In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may further include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to antibodies or binding fragments thereof that binds to said immunogenic compositions. In further aspects, the invention relates to isolated nucleotide sequences that encode any of the foregoing, and methods of use of any of the foregoing compositions.

公开(公告)号：US09187536B1

公开(公告)日：2015-11-17

申请号：US14796741

申请日：2015-07-10

申请人： WYETH LLC

发明人： Annaliesa Sybil Anderson ,  Maninder K. Sidhu ,  Robert G. K. Donald ,  Kathrin Ute Jansen ,  Narender K. Kalyan ,  Justin Keith Moran ,  Mark E. Ruppen ,  Michael James Flint

IPC分类号： C12N9/10 ,  C07K14/33 ,  A61K39/00 ,  A61K39/08

CPC分类号： C07K14/33 ,  A61K39/08 ,  C07K16/1282 ,  C07K2317/33 ,  C07K2317/76 ,  C07K2317/92 ,  C12N9/1051 ,  C12N9/99 ,  C12N15/74

摘要： In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may further include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to antibodies or binding fragments thereof that binds to said immunogenic compositions. In further aspects, the invention relates to isolated nucleotide sequences that encode any of the foregoing, and methods of use of any of the foregoing compositions.

摘要翻译： 一方面，本发明涉及包含突变型艰难梭菌毒素A和/或突变型艰难梭菌毒素B的免疫原性组合物。每种突变毒素包括具有至少一个突变的葡糖基转移酶结构域和具有至少一个突变的半胱氨酸蛋白酶结构域 突变，相对于相应的野生型艰难梭菌毒素。 突变毒素还可以包括至少一个化学交联的氨基酸。 另一方面，本发明涉及结合所述免疫原性组合物的抗体或其结合片段。 在另外的方面，本发明涉及编码前述任何一种的分离的核苷酸序列，以及任何上述组合物的使用方法。

公开(公告)号：US20130244307A1

公开(公告)日：2013-09-19

申请号：US13848909

申请日：2013-03-22

申请人： WYETH LLC

发明人： Annaliesa Sybil Anderson ,  Maninder K. Sidhu ,  Robert G. K. Donald ,  Kathrin Ute Jansen ,  Narender K. Kalyan ,  Terri L. Mininni ,  Justin Keith Moran ,  Mark E. Ruppen ,  Michael James Flint

IPC分类号： C12N15/74

CPC分类号： C07K14/33 ,  A61K39/08 ,  C07K16/1282 ,  C07K2317/33 ,  C07K2317/76 ,  C07K2317/92 ,  C12N9/1051 ,  C12N9/99 ,  C12N15/74

摘要： In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may further include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to antibodies or binding fragments thereof that binds to said immunogenic compositions. In further aspects, the invention relates to isolated nucleotide sequences that encode any of the foregoing, and methods of use of any of the foregoing compositions.

公开(公告)号：US20190202873A1

公开(公告)日：2019-07-04

申请号：US16359267

申请日：2019-03-20

申请人： Wyeth LLC

发明人： Kathrin Ute Jansen ,  Annaliesa Sybil Anderson ,  Robert G.K. Donald ,  Maninder K. Sidhu ,  Narender Kumar Kalyan ,  Justin Keith Moran ,  Mark Edward Ruppen ,  Michael James Flint

IPC分类号： C07K14/33 ,  A61K39/08 ,  C12N9/99 ,  C12N9/10 ,  C07K16/12 ,  C12N15/74

摘要： In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may further include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to antibodies or binding fragments thereof that binds to said immunogenic compositions. In further aspects, the invention relates to isolated nucleotide sequences that encode any of the foregoing, and methods of use of any of the foregoing compositions.

公开(公告)号：US08889145B2

公开(公告)日：2014-11-18

申请号：US14032534

申请日：2013-09-20

申请人： Wyeth LLC

发明人： Annaliesa Anderson ,  Viliam Pavliak ,  Kathrin Ute Jansen ,  Ingrid Lea Scully ,  Steven Morris Baker ,  Jasdeep Singh Nanra ,  Ellen Murphy ,  Bruce Arthur Green ,  Mark Edward Ruppen ,  Yekaterina Timofeyeva

IPC分类号： A61K39/085 ,  A61K39/40 ,  C07K16/12 ,  A61K39/00

CPC分类号： A61K39/085 ,  A61K2039/505 ,  A61K2039/55505 ,  A61K2039/6031 ,  A61K2039/6037 ,  C07K16/1271 ,  C07K2317/21 ,  C07K2317/73

摘要： The present invention relates to immunogenic compositions, comprising polypeptides and polysaccharides from Staphylococcus aureus. The present invention also relates to immunogenic compositions, comprising Staphylococcus aureus capsule polysaccharides conjugated to a carrier protein. In addition, the invention relates to methods of inducing an immune response in subjects against Staphylococcus aureus using immunogenic compositions of the Staphylococcus aureus polypeptides and capsule polysaccharides.

摘要翻译： 本发明涉及包含来自金黄色葡萄球菌的多肽和多糖的免疫原性组合物。 本发明还涉及包含与载体蛋白缀合的金黄色葡萄球菌胶囊多糖的免疫原性组合物。 此外，本发明涉及使用金黄色葡萄球菌多肽和胶囊多糖的免疫原性组合物在金黄色葡萄球菌受试者中诱导免疫应答的方法。

公开(公告)号：US20130330371A1

公开(公告)日：2013-12-12

申请号：US13970048

申请日：2013-08-19

申请人： WYETH LLC

发明人： Annaliesa Sybil Anderson ,  Maninder K. Sidhu ,  Robert G. K. Donald ,  Kathrin Ute Jansen ,  Narender Kumar Kalyan ,  Justin Keith Moran ,  Mark E. Ruppen ,  Michael James Flint

IPC分类号： C12N9/10 ,  C12N9/99

CPC分类号： C07K14/33 ,  A61K39/08 ,  C07K16/1282 ,  C07K2317/33 ,  C07K2317/76 ,  C07K2317/92 ,  C12N9/1051 ,  C12N9/99 ,  C12N15/74

摘要： In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may further include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to antibodies or binding fragments thereof that binds to said immunogenic compositions. In further aspects, the invention relates to isolated nucleotide sequences that encode any of the foregoing, and methods of use of any of the foregoing compositions.